The first stop for professional medicines advice

Medicines planning

61 results

Applied filters

Good governance when implementing ranibizumab biosimilar

29 June 2022Governance should consider processes for approval; procurement and supply; prescribing and administration; monitoring; and pharmacovigilance

The licence and supporting evidence for ranibizumab biosimilars

29 June 2022Four licensed ranibizumab biosimilars are available: Byooviz, Ongavia, Rimmyrah and Ximluci. Learn about the licensed indications and supporting evidence

Understanding biological and biosimilar medicines

29 June 2022Biosimilar medicines are a type of biological medicine that offer the NHS opportunities to deliver better value for certain conditions

How to develop a Patient Group Direction

9 June 2022A guide to help organisations and individuals navigate all stages of the PGD development process.

Patient Group Direction use in remote consultations

3 February 2022Patient Group Directions (PGDs) may be used to supply medicines via remote consultations. Advice on clinical assessment and supply is provided.

Including more than one medicine in a Patient Group Direction

2 December 2021This article summarises the considerations required if more than one medicine is included within a single PGD.

Using medicines at more than one location under a single PGD

16 November 2021A single Patient Group Direction (PGD) can be used to supply or administer medicines in more than one location. PGDs do not need to relate to specific premises.

NHS prescription charges for PGDs or HMR 2012 exemptions

16 November 2021This article summarises the position regarding the levying of prescription charges for medicines supplied under a PGD or an exemption to the HMR 2012.

Annual medicines planning

Our annual Prescribing Outlook outputs support planning, implementation and budget planning for medicines every year.
Registration required

Summary of biopharmaceutical stability data reviewed and available extended shelf-life data

4 June 2021The stability of several aseptically compounded ready to administer presentations of monoclonal antibody products and other biopharmaceuticals is presented.
admin